Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Queen Mary University of London · Histogen (United States) · +22 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
566
total citations
- FWCI
- 64.68
- Percentile
- 100%
- References
- 27
Citations per year
Authors
25- TPThomas PowlesCorresponding
Queen Mary University of London
- MKMark Kockx
Histogen (United States), HistoGeneX (Belgium)
- ARAlejo Rodríguez‐Vida
Hospital Del Mar
- IDIgnacio Durán
Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla
- SJSimon J. Crabb
NIHR CRUK Experimental Cancer Medicine Centre, University of Southampton
Topics & keywords
Topics
Keywords
- Atezolizumab
- Biomarker
- Oncology
- Medicine
- Clinical endpoint
- Bladder cancer
- Internal medicine
- Gene signature
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.